Mirum Pharmaceuticals Stock Price, News & Analysis

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has initiated an underwritten public offering to raise $80.0 million in common stock, with an option for underwriters to purchase an additional $12.0 million. The offering follows a shelf registration statement declared effective by the SEC on August 12, 2020. J.P. Morgan, SVB Securities, and Evercore ISI are leading the offering, but no assurance is given regarding its completion or terms. Mirum is known for its focus on treatments for rare liver diseases, including the approved LIVMARLI® and ongoing clinical trials for various conditions.

Mirum Pharmaceuticals reported a net product sales figure of $17.5 million for LIVMARLI in Q2 2022, bringing year-to-date sales to $28.4 million. While total operating expenses rose slightly to $48.9 million, R&D expenses decreased to $25.4 million. The company recorded a net loss of $26.9 million, a reduction from $43.9 million in Q2 2021. Anticipated milestones include EMA approval for Alagille syndrome and Phase 3 data for PFIC trials later this year. A conference call for further updates is scheduled for August 4, 2022.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is set to report its second quarter financial results on August 4, 2022, at 4:30 p.m. ET. The company will host a conference call to discuss its progress and priorities for 2022. Mirum’s pipeline includes treatments for rare liver diseases, with its approved drug, LIVMARLI®, targeting cholestatic pruritus in Alagille syndrome patients. The company is also advancing several investigational treatments, including volixibat for primary sclerosing cholangitis and ongoing clinical trials for pediatric liver diseases.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced on July 8, 2022, the grant of stock options and restricted stock units (RSUs) totaling 64,500 shares to seven new employees under its 2020 Inducement Plan. The stock options have an exercise price of $23.86 per share, vesting over four years, while the RSUs will vest over three years. This is part of the company's strategy to attract talent amidst its growth in developing treatments for rare diseases, including its approved drug LIVMARLI® and investigational treatments for liver diseases.

Mirum Pharmaceuticals presented significant findings from clinical studies on maralixibat at the 54th Annual ESPGHAN Meeting. The data showed a 70% reduction in event-free survival and significant improvements in transplant-free survival in patients with Alagille syndrome. Notably, 76% and 79% of patients remained event-free and transplant-free at six years. Maralixibat also demonstrated improved growth in pediatric patients over four years.

Furthermore, the treatment showed a notable impact on health-related quality of life, particularly in patients with BSEP deficiency. This data enhances the understanding of maralixibat's clinical potential.

Mirum Pharmaceuticals (NASDAQ: MIRM) presented significant findings at the 2022 International Liver Congress in London, highlighting the debilitating effects of pruritus on patients with primary sclerosing cholangitis (PSC). A multinational survey with 482 patients revealed that 91% experienced itch, severely impacting their quality of life. Importantly, current treatments provided limited relief. Mirum is evaluating volixibat, an IBAT inhibitor, to address this unmet need. The company is also exploring optimal dosing strategies for its drugs in clinical trials.

Mirum Pharmaceuticals (Nasdaq: MIRM) presents data at the International Liver Congress™ and the 54th Annual ESPGHAN Meeting. Eight abstracts are accepted, including three oral presentations, with notable research on maralixibat for Alagille syndrome. This data includes predictors of event-free survival and is nominated for the prestigious Alex Mowat Prize. Additionally, Mirum will host scientific symposia at both events, enhancing its position in the treatment of rare liver diseases.

On June 10, 2022, Mirum Pharmaceuticals granted inducement awards under its 2020 Inducement Plan to eight new employees. These awards consist of non-qualified stock options for 43,550 shares and 21,800 restricted stock units (RSUs). The stock options have an exercise price of $21.36 and will vest over four years, while RSUs will vest over three years. The awards comply with Nasdaq Listing Rule 5635(c)(4) and are aimed at incentivizing the new hires to drive growth in Mirum's rare disease treatments.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the appointment of Saira Ramasastry to its board of directors and audit committee. Ramasastry brings over 20 years of financial leadership, including her experience at Merrill Lynch & Company. CEO Chris Peetz emphasized her strategic experience as crucial for expanding the company’s reach and enhancing its rare disease pipeline. Mirum develops therapies like LIVMARLI® for liver diseases and has ongoing clinical trials for innovative treatments, showing commitment to advancing care for patients.